CYP2D6 Genotyping and the Clinical Impact on Outcomes in Breast Cancer Tamoxifen-Treated Patients

Abstract

Aims: To report the distribution of allele frequencies of CYP2D6 gene and to evaluate their influence on the clinical outcomes of a group of breast cancer patients receiving adjuvant tamoxifen treatment from Uruguay. Patients&methods: 199 samples were genotyped through real-time polymerase chain reaction assays. Metabolization profiles were inferred from the genotypes. Correlations were evaluated using Pearson’s χ² test. Results: Phenotype frequencies were 0.65 normal (NM), 0.30 intermediate (IM) and 0.05 poor metabolizers (PM). Similar clinical outcomes between NM and (PM + IM) patient groups (odds ratio = 1.011, 95% CI = 0.2703–3.7826; p = 0.987) were found. Conclusion: CYP2D6 allele frequencies were analyzed for the first time in a cohort from Uruguay. Results did not support any impact of CYP2D6 gene polymorphisms on clinical outcomes.

Keywords: :

• breast cancer
• CYP2D6
• tamoxifen

Author contributions

G Ramírez: methodology and data analysis, writing – original draft. M Vital: writing – review and editing. F Carusso, F Neffa and C Valle: sample preparation, data collection. A Della Valle and P Esperón: conception and design. PE: writing – review and editing; supervision. All authors reviewed the manuscript.

Financial disclosure

The authors have no financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending or royalties.

Competing interests disclosure

The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending or royalties.

Writing disclosure

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The Bioethical Boards of the School of Chemistry and the Armed Forces Hospital approved the study, and it was in accordance with the current version of the Helsinki Declaration. A signed informed consent was obtained from all individual participants.